Literature DB >> 21482677

Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.

Dominique S Meyer1, Heike Brinkhaus, Urs Müller, Matthias Müller, Robert D Cardiff, Mohamed Bentires-Alj.   

Abstract

The phosphoinositide 3-kinase (PI3K) signaling cascade, a key mediator of cellular survival, growth, and metabolism, is frequently altered in human cancer. Activating mutations in PIK3CA, which encodes the α-catalytic subunit of PI3K, occur in approximately 30% of breast cancers. These mutations result in constitutive activity of the enzyme and are oncogenic, but it is not known whether they are sufficient to induce mammary carcinomas in mice. In the present study, we show that the expression of mutant PIK3CA H1047R in the luminal mammary epithelium evokes heterogeneous tumors that express luminal and basal markers and are positive for the estrogen receptor. Our results suggest that the PIK3CA H1047R oncogene targets a multipotent progenitor cell and, furthermore, show that this model recapitulates features of human breast tumors with PIK3CA H1047R. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482677     DOI: 10.1158/0008-5472.CAN-10-3827

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

Review 1.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Authors:  Todd W Miller; Justin M Balko; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

Review 2.  The Cellular Origin and Evolution of Breast Cancer.

Authors:  Mei Zhang; Adrian V Lee; Jeffrey M Rosen
Journal:  Cold Spring Harb Perspect Med       Date:  2017-03-01       Impact factor: 6.915

3.  Intraductal Injection of Lentivirus Vectors for Stably Introducing Genes into Rat Mammary Epithelial Cells in Vivo.

Authors:  Wen Bu; Yi Li
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-11-09       Impact factor: 2.673

4.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Authors:  Kathryn M Kinross; Karen G Montgomery; Margarete Kleinschmidt; Paul Waring; Ivan Ivetac; Anjali Tikoo; Mirette Saad; Lauren Hare; Vincent Roh; Theo Mantamadiotis; Karen E Sheppard; Georgina L Ryland; Ian G Campbell; Kylie L Gorringe; James G Christensen; Carleen Cullinane; Rodney J Hicks; Richard B Pearson; Ricky W Johnstone; Grant A McArthur; Wayne A Phillips
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 5.  How can grafted breast cancer models be optimized?

Authors:  Séverine Mollard; Yoanne Mousseau; Yasser Baaj; Laurence Richard; Jeanne Cook-Moreau; Jacques Monteil; Benoît Funalot; Franck G Sturtz
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

Review 6.  Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells.

Authors:  Patrick D Rädler; Barbara L Wehde; Kay-Uwe Wagner
Journal:  Mol Cell Endocrinol       Date:  2017-05-08       Impact factor: 4.102

7.  Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.

Authors:  Jeffrey W Schmidt; Barbara L Wehde; Kazuhito Sakamoto; Aleata A Triplett; Steven M Anderson; Philip N Tsichlis; Gustavo Leone; Kay-Uwe Wagner
Journal:  Mol Cell Biol       Date:  2014-01-27       Impact factor: 4.272

Review 8.  Genetically engineered mouse models of PI3K signaling in breast cancer.

Authors:  Sjoerd Klarenbeek; Martine H van Miltenburg; Jos Jonkers
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

9.  Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.

Authors:  A M Gonzalez-Angulo; G R Blumenschein
Journal:  Cancer Treat Rev       Date:  2012-12-06       Impact factor: 12.111

10.  Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation.

Authors:  Zheng Zhang; John R Christin; Chunhui Wang; Kai Ge; Maja H Oktay; Wenjun Guo
Journal:  Cell Rep       Date:  2016-09-20       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.